title: Disodium-fosfomycin pharmacokinetics and bioavailability in post weaning piglets.
abstract: Disodium-fosfomycin pharmacokinetics has been studied in different species after oral, intravenous, intramuscular and subcutaneous administration. At present there are neither documented clinical experiences of the use of fosfomycin in pigs nor any published studies in weaning piglets, although it is a period of high incidence of infectious diseases. The pharmacokinetics and the bioavailability of sodium fosfomycin were studied in post weaning piglets after intravenous and intramuscular administration of 15 mg/kg of body weight. Plasma concentrations were measured by a high-performance liquid ms/ms. After IV administration the area under the fosfomycin concentration:time curve in plasma was AUC(0-12) of 120.00 ± 23.12 μg h/ml and the volume of distribution (Vd) of 273.00 ± 40.70 ml/kg. The elimination was rapid with a plasma clearance of 131.50 ± 30.07 ml/kg/h and a T(1/2) of 1.54 ± 0.40 h. Peak serum concentration (Cmax), Tmax, AUC(0-12) and bioavailability for the IM administration were 43.00 ± 4.10 μg/ml, 0.75 ± 0.00 h, 99.00 ± 0.70 μg h/ml and 85.5 ± 9.90% respectively. Different authors have determined a minimum inhibitory concentration (MIC90) ranging from 0.25 μg/ml for Streptococcus sp. and 0.5 μg/ml for Escherichia coli. Considering the above, and according to the values of plasma concentration vs time profiles observed in this study, effective plasma concentrations of fosfomycin for sensitive bacteria can be obtained following IV and IM administration of 15 mg/kg in piglets.
authors.affiliation: Área Toxicología, Departamento de Fisiopatología, Facultad de Ciencias Veterinarias, Universidad Nacional del Centro de la Provincia de Buenos Aires, Tandil, Argentina. alejandro@vet.unicen.edu.ar
authors.forename: A L
authors.initials: AL
authors.lastname: Soraci
authors.forename: D S
authors.initials: DS
authors.lastname: Perez
authors.forename: G
authors.initials: G
authors.lastname: Martinez
authors.forename: S
authors.initials: S
authors.lastname: Dieguez
authors.forename: M O
authors.initials: MO
authors.lastname: Tapia
authors.forename: F
authors.initials: F
authors.lastname: Amanto
authors.forename: R
authors.initials: R
authors.lastname: Harkes
authors.forename: O
authors.initials: O
authors.lastname: Romano
mesh_terms: D000818:Animals; D000831:Animals, Newborn / Q000378:metabolism; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid / Q000662:veterinary; D005260:Female; D005578:Fosfomycin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D007273:Injections, Intramuscular / Q000662:veterinary; D007275:Injections, Intravenous / Q000662:veterinary; D008297:Male; D013552:Swine; D014886:Weaning
chemical_list: D000900:Anti-Bacterial Agents; D005578:Fosfomycin